Modality
Multispecific
MOA
EGFRi
Target
CD38
Pathway
Lipid Met
FSGS
Development Pipeline
Preclinical
~Sep 2017
→ ~Dec 2018
Phase 1
~Mar 2019
→ ~Jun 2020
Phase 2
Sep 2020
→ Jan 2026
Phase 2Current
NCT03342072
421 pts·FSGS
2020-09→2026-01·Not yet recruiting
421 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-01-222mo agoPh2 Data· FSGS
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P2
Not yet…
Catalysts
Ph2 Data
2026-01-22 · 2mo ago
FSGS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03342072 | Phase 2 | FSGS | Not yet recr... | 421 | EASI-75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Niranesiran | Johnson & Johnson | Phase 2 | KIF18A | |
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| GSK-2051 | GSK | Phase 1 | PSMA | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 |